Although the use of endocrine agents that block estrogen production (AIs) or block ER function (SERM/SERD) are front-line therapies to treat metastatic ER+ breast cancer, the use of high-dose estrogens has also been reported to be effective. The gene discussed is ESR1; the disease is breast cancer.